Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Affluent Medical annonce des résultats prometteurs pour son sphincter urinaire artificiel Artus et obtient l’autorisation de lancer la phase pivot de son essai clinique.
Regulatory Filings Classification · 95% confidence The document is titled with a headline announcing 'Affluent Medical annonce des résultats prometteurs pour son sphincter urinaire artificiel Artus et obtient l'autorisation de lancer la phase pivot de son essai clinique' and is explicitly labeled as a 'COMMUNIQUÉ DE PRESSE' (Press Release). It details clinical trial progress, safety profiles, efficacy data, and management commentary. This structure strongly indicates an initial announcement of periodic or significant operational/financial news, which aligns best with the 'Earnings Release' (ER) category, even though the content is clinical trial progress rather than quarterly revenue figures. Since it is a formal announcement of results/progress, it is not a general Regulatory Filing (RNS) or a Report Publication Announcement (RPA) which typically just points to another document. Given the options, ER is the closest fit for a formal press release detailing key performance indicators (clinical results).
2025-05-15 French
Affluent Medical announces promising performance results for its Artus artificial urinary sphincter and receives approval to initiate pivotal phase of its clinical trial
Regulatory Filings Classification · 100% confidence The document is a press release dated May 15, 2025, announcing positive performance results for a medical device (Artus artificial urinary sphincter) and clearance to start the pivotal phase of a clinical trial. It contains key highlights, management commentary, and company background, typical of an initial results announcement rather than a comprehensive periodic report (like 10-K or IR). Since it announces preliminary performance results and clinical progress, it aligns best with an Earnings Release (ER) category, which often includes operational updates alongside financial highlights, or potentially Regulatory Filings (RNS) if it were purely regulatory. Given the focus on 'promising performance results' and clinical milestones, ER is the most appropriate fit among the specific financial/operational categories, as it serves as an immediate update to the market about recent operational success that impacts future earnings potential. It is not a full transcript (CT), a formal annual/interim report (10-K/IR), or a management discussion (MDA).
2025-05-15 English
Affluent Medical : Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.25
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it provides 'Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des Marchés Financiers (AMF)'. It details the number of shares and voting rights as of a specific date (30/04/2025). This type of mandatory disclosure regarding share capital structure and voting rights, often published monthly or periodically in France, is a specific regulatory filing. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue (SHA). It is a specific regulatory disclosure concerning ownership/voting rights thresholds, which aligns best with the general regulatory filing category (RNS) or potentially a specific disclosure related to share structure, but given the context of mandatory reporting on voting rights, RNS is the most appropriate general regulatory bucket if a more specific one like 'Major Shareholding Notification' (MRQ) doesn't fit perfectly (MRQ is usually for crossing thresholds, this is a periodic update). However, since the content is a direct report of share/vote counts mandated by French regulation (AMF), it is a regulatory filing. Given the options, and the nature of reporting share capital structure updates, it is a specific regulatory disclosure. If we look closely at the definitions, none perfectly match a periodic 'Number of Shares Outstanding' report. 'SHA' is for share *issue/change*, not periodic reporting of the total. 'MRQ' is for *major shareholding notification* (crossing thresholds). Since this is a mandatory periodic disclosure of the total share count and voting rights, it falls under general regulatory reporting. I will classify it as RNS (Regulatory Filings) as the best fit for a mandatory, non-periodic financial/governance disclosure that doesn't fit elsewhere.
2025-05-15 French
Affluent Medical : Mise à disposition du Document d’Enregistrement Universel (DEU) 2024.
Report Publication Announcement Classification · 98% confidence The document is a press release titled "Mise à disposition du Document d'Enregistrement Universel (DEU) 2024" (Making available of the 2024 Universal Registration Document). It explicitly states that the DEU 2024, which contains the annual financial report, management report, and corporate governance report, has been filed with the AMF and is now available to the public. Since the document's primary function is to announce the publication/availability of a major report (the DEU, which encompasses the 10-K equivalent information for this jurisdiction), and the document length is relatively short (3410 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full report itself (10-K or AR). Key indicators: "annonce aujourd'hui la mise à disposition du public" (announces today the making available to the public) and the short length, triggering the 'MENU VS MEAL' rule.
2025-05-02 French
Affluent Medical : Document d'Enregistrement Universel 2024 incluant le rapport financier annuel.
Annual Report
2025-05-02 French
Document d'enregistrement universel 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-30 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.